Biomarker-driven selection, circulating tumor DNA for minimal residual disease, resistance-associated alterations (e.g., CTNNB1), and etiology-linked immune phenotypes, will be central to optimizing patient selection and treatment sequencing. The gene discussed is CTNNB1; the disease is neoplasm.